Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.34 0.1299 +61.86%
GALT $5.31 0.4496 +9.25%
PVCT $0.99 0.0799 +8.78%
AGIO $43.07 2.7150 +6.73%
MGNX $22.10 1.1800 +5.64%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CERU $4.41 -0.2600 -5.57%
IMNP $3.74 -0.2099 -5.31%
CRIS $1.57 -0.0850 -5.15%
CBMG $17.85 -0.9200 -4.90%
GLYC $7.74 -0.2400 -3.01%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

NCI SBIR Launches New Regulatory Assistance Program

(NCI SBIR & STTR) Jan 13, 2011 - The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs have announced the launch of a new Regulatory Assistance Program.
read press release 

First Firefighter to Die Since Signing of 9/11 Health Law Is Recalled as a Leader

(New York Times) Jan 12, 2011 – Mr. Chelsen, 51, first got sick about five years ago. He died after a five-year battle with multiple myeloma, a cancer that the New York Fire Department, his relatives and others consider to have been linked to his service on 9/11 — and his work in the ensuing weeks searching the rubble for lost colleagues.
read article (free registration required) 

EPA Encourages Regular Testing for Heavy Metal in Water

(Los Angeles Times) Jan 11, 2011 - Cancer-causing hexavalent chromium, which garnered attention from the movie 'Erin Brockovich,' was found in tap water from Chicago and more than two dozen other cities.
read article (free registration required) 

Biotech Firms Fight Generics

(Wall Street Journal) Jan 13, 2011 - Brand-name drug companies are fighting to weaken a provision of the health overhaul that was designed to open up generic competition in biotechnology medicines and save billions of dollars.
read article (paid subscription required) 

Merck Learns There Is No Magic Pill

(Forbes The Medicine Show Blog) Jan 13, 2010 - The potential for the most exciting experimental drug Merck got from its $41 billion purchase of smaller rival Schering-Plough just took a big hit.
read article 

FDA Panel Rejects Lilly Pancreatic-Enzyme Replacement

(Dow Jones Newswires/Morningstar) Jan 12, 2011 - A Food and Drug Administration panel rejected a new type of pancreatic-enzyme replacement product developed by an Eli Lilly & Co. unit on concerns the drug isn't effective.
read article 

FDA Limits Acetaminophen

(Washington Post/The Checkup Blog) Jan 13, 2011 - Federal health officials Thursday announced they are taking steps to prevent people from suffering severe liver damage by taking products containing the popular painkiller acetaminophen.
read article (free registration required) 

Google’s Eric Schmidt Says Open Source Could Be The Way To Go In Health IT

(Forbes Healthworks Blog) Jan 13, 2011 - J.P. Morgan hosted its first health IT panel ever at its annual Healthcare Conference in San Francisco at which Kleiner Perkins’ John Doerr, who is no stranger to Health IT, was the moderator. He has funded his brother Tom Doerr, a physician who has developed an electronic health record (EHR) for small practices.
read article 

Surveys Show Significant Proportions of Hospitals and Doctors Already Plan to Adopt Electronic Health Records and Qualify for Federal Incentive Payments

( Jan 13, 2011 - Four-fifths of the nation’s hospitals, and 41 percent of office-based physicians, currently intend to take advantage of federal incentive payments for adoption and meaningful use of certified electronic health records (EHR) technology, according to survey data released today by the Office of the National Coordinator for Health Information Technology (ONC).
read press release 

Opinion: The FDA Needs Strong Medicine

(Forbes) Jan 12, 2011 - The organization is due for an overhaul--starting with a new deputy commissioner.
read article 

FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV

(Eisai) Jan 12, 2011 - Helsinn Group and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
read press release 

Pfizer Initiates Rolling Submission For A New Drug Application In The U.S. For Its Fast-Tracked Investigational Compound Crizotinib (PF-02341066) For Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

(Yahoo! Finance) Jan 12, 2011 - Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive.
read article 

Sanofi’s Taxotere Extends Life in Head, Neck Cancer in Study

(Bloomberg) Jan 11, 2011 - Adding Sanofi-Aventis SA’s Taxotere to two other medicines significantly improved long-term survival of patients with head and neck cancer, according to research published today in the journal The Lancet Oncology.
read article 

Gentlemen, Start Your Kegels! Study Looks at Incontinence Treatment

(WSJ Health Blog) Jan 11, 2011 - A study published in the Journal of the American Medical Association finds that therapy to help men learn exercises to build up their pelvic-floor muscles can help address the problem of incontinence following surgery to remove a cancerous prostate gland.
read article (paid subscription required) 

Scientists Say Drug Stops Pancreatic Cancer in Early Stages

(Milwaukee Journal Sentinel) Jan 12, 2011 - Researchers at the University of Oklahoma report that a drug used in chemotherapy given to patients in the later stages of pancreatic cancer shows great promise when given much earlier.
read article 

Too Many Cancer Screening Options Confuse Patients and Lead Them to Avoid Screenings Altogether, Finds VCU Massey Cancer Center

(VCU Massey) Jan 10, 2011 - Adhering to cancer screening recommendations is one of the best things people can do to reduce their risk of dying from cancer.
read press release 

Two-Faced Proteins?

(The Scientist) Jan 11, 2011 – Cancer researchers are identifying an increasing number of proteins that have a dual nature when it comes to cancer -- they may initially promote the development of tumors, but in the long run make them less aggressive, or vice versa.
read article 

Measles Virus, a Weapon Against Cancer?

(University of Texas Medical Branch) Jan 12, 2011 - When most people in the developed world think of measles, what comes to mind is only a dim memory of a vaccination at a pediatrician's office. But while childhood vaccination has virtually eliminated measles from North America and much of Europe, researchers remain interested in the virus.
read press release 

Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient into Global Phase 3 Trial for ARQ 197

(Morningstar) Jan 12, 2011 - Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
read article 

The U.S. National Cancer Institute Starts a Phase II Clinical Trial with Innate Pharma's IPH 2101

(Innate Pharma) Jan 12, 2011 - Innate Pharma announces that the National Cancer Institute has enrolled a first patient in a new Phase II clinical trial testing Innate Pharma’s anti-KIR monoclonal antibody IPH 2101, in patients with smoldering myeloma, an early stage of the blood malignancy multiple myeloma.
read press release 

Multiple Myeloma Research Foundation (MMRF) and Synta Pharmaceuticals Enter into Joint Collaboration to Accelerate Drug Development for Myeloma Patients

(Synta) Jan 12, 2011 - The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.
read press release 

UCSF, Sanofi Ink Research, Intern Deal

(San Francisco Business Times) Jan 12, 2011 - French drug maker Sanofi-Aventis will fund up to five UCSF cancer research projects a year and allow UCSF students or fellows to conduct research as company interns.
read article 

Government Aims to Save More Cancer Patients by 2015

(Reuters) Jan 12, 2011 - The government said on Wednesday it wants to save 5,000 more cancer patients a year by 2015 and outlined 750 million pounds worth of extra spending on care over the next four years to improve survival rates.
read article 

Physicians Need Help Choosing Best Gene Test for Cancer Patient Relatives

(Baylor) Jan 12, 2011 - Better physician education and consultation with genetics professionals when recommending genetic testing for healthy relatives of cancer patients could lower costs and increase the value of the testing, said a cancer geneticist from the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine, who surveyed physicians to determine their level of knowledge.
read press release 

Biomoda Adds Clinical Site to Lung Cancer Study

(StreetInsider) Jan 12, 2011 - Cancer diagnostics company Biomoda, Inc. announced that Waterbury Pulmonary Associates Research has joined the pilot clinical study of Biomoda’s CyPath® diagnostic assay.
read article